Tianxing Zhou. "A phase 2 study of vilanterol in combination with a CLDN18.2 bispecific antibody in patients with advanced CLDN18.2-positive pancreatic ductal adenocarcinoma (PDAC).." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.2_suppl.748